Combined analyses of concurrent variation in CYP2B6, CYP2A6 and CHRNA5-A3-B4 appeared to stratify ever-smokers by lung cancer risk supporting an important role for variation in both nicotine/nitrosamine pharmacokinetic and pharmacodynamic pathways to the risk for lung cancer among smokers. This evidence concerns the gene CYP2A6 and lung carcinoma.